Category Archives: Cf

Im always nervous about diving back into work after being out of commission. In this case, Im referring to the monthlong hiatusI took from writing this column. I was hesitant to pause my writing for Cystic Fibrosis News Today. What if I disappoint my editors or my audience? Even worse, what if I ignore my declining health? The latter is an ongoing battle.

Fortunately, I was productive during my month off. In addition to several trips to the emergency room related to my sinuses, I watched video of the London stage production Heathers the Musical, a dark comedy that follows Veronica Sawyer through a dangerous high school romance. Ive written about the show before in a column titled Big Fun: My Make-A-Wish, but this production featured a new cast. Further, I was surprised to learn that this version featured several new songs, including I Say No.

In the song, Veronica vocalizes how unhealthy her relationship has become. From acceptance to validation, the lyrics were a great addition to the story and my audition book.

This is it/ Hit the brake/ I am finally awakeVeronica took a moment to address and accept the things that were out of her control. In my case, I must accept that breaks are necessary.

As a cystic fibrosis (CF) patient, I found that pitting my health against my happiness was an ongoing Sophies choice, so I tended to work my body into the ground before coming to a full stop. As a post-transplant patient, however, my lungs force me to rest, and I decided I must follow their lead. I dont want to put my new lungs in jeopardy, nor do I want the quality of my work to suffer.

Either way, saying no is a necessary tool during periods of infection, but pushing myself is a tough habit to break.

Call it all my mistake/ long as you let me go

As hard as it is to rest, though, its twice as hard to dive back in, for three primary reasons.

One, my mind and body grow accustomed to the out of commission lifestyle. The longer I rest, the harder it is to bounce back. Im encouraged and required to rest more than usual. My emotions and immunity become even more vulnerable. I become overwhelmed by appointments and medications, and my family must step in. Being cared for is addictive, and that addiction skews my ability to identify my bounce-back period.

Two, the fear of my full-speed life paralyzes me. The little voice inside of my head, the one that grows louder with every nap or additional antibiotic, tells me that Im powerless. My symptoms, the mindset, and the situation trick me into thinking Im incapable of diving back in. Or worse, Im convinced the act of diving in is irresponsible or unrealistic.

Three, my family asks if Ill join them for dinner or at a local festival that I enjoy and I say no. I become intimidated by my previous self, even if that self existed a short time ago. What if I cant bounce back quickly enough or cant endure? Are these thoughts pessimistic or responsible? I cant write, or walk, or be.

Ive got to kick this habit now/ or else I never will I wont cry/ starting now, I will try

In lieu of stopping my column completely, I decided to decrease the frequency of it from four times a month to just twice. Im not sure if this change is temporary or permanent, but its whats best for this stage of my life.

Veronica reflected on each step of her emotional journey, and the lyrics encouraged me to explore my own issues with stepping away versus diving back in.

Im still nervous that I have nothing good to say, that my endurance wont last. Will I be expected to keep up with the previous standards that Ive set for myself and my writing? If so, should I warn my audience that I might not be able to do so? Should I have faith that I can, or simply dive in and see what happens?

If youre also scared to dive back in, worrying youre not good enough, concerned you cant compete with your previous self, or anxious that youll run out of things to say just take that first step. Write something. Walk somewhere. Its enough.

To the situation that tells me Im a failure for slowing down; to my CF, whose statistics and symptoms twist the truth and force me to question my identity; to the feeling that I must permanently sit on the couch: I say no.

Nicole in the CarolinaEast Medical Center emergency room on Sept. 25. (Courtesy of Nicole Kohr)

Note:Cystic Fibrosis News Todayis strictly a news and information website about the disease. It does not provide medical advice,diagnosis, ortreatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofCystic Fibrosis News Todayor its parent company, BioNews, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read more here:

The Difficulties of Diving Back In After Taking a Hiatus | Cystic... - Cystic Fibrosis News Today

The overall cystic fibrosis market is expected to surge due to the increasing prevalence of the disease and expected launch of emerging therapies including Ensifentrine, VX-121/TEZ/ VX561, and others in the forecasted period (20222032).

LAS VEGAS, Oct. 12, 2022 /PRNewswire/ --DelveInsight's Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Takeaways from the Cystic Fibrosis Market Report

Discover which therapies are expected to grab the major cystic fibrosis market share @Cystic Fibrosis Market Report

Cystic Fibrosis Overview

Cystic fibrosis is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most common variation reported globally, but there are over 2000 others, not all causing the disease.

The cystic fibrosis symptoms usually appear 6-8 months after birth, though this varies significantly from person to person. Cystic fibrosis symptoms vary with age and can affect different body parts. Newborn screening, a genetic test to look for a gene defect, and a blood test to look for pancreatic problems are two tests used for cystic fibrosis diagnosis. After initial testing, a sweat test can be performed to confirm the cystic fibrosis diagnosis.

Cystic Fibrosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 65.5K diagnosed prevalent cases of cystic fibrosis in the 7MM in 2021.

Among the EU5 countries, the UK had the highest number of cystic fibrosis diagnosed prevalent cases in 2021.

The cystic fibrosis market reportproffers epidemiological analysis for the study period 20192032 in the 7MM segmented into:

Download the report to understand which factors are driving cystic fibrosis epidemiology trends @Cystic Fibrosis Epidemiological Insights

Cystic Fibrosis Treatment Market

Current cystic fibrosis medications focus on symptom relief, complication prevention, and, more recently, protein rectifiers to correct underlying structural and functional abnormalities. Inhaled antibiotics are used to treat chronic lung infections, mucolytics are used to reduce the viscosity of pulmonary mucus, pancreatic enzyme replacement therapy (PERT) is used to treat CF-associated exocrine pancreatic insufficiency (PPI), and CFTR modulators are used to improve CFTR function while addressing the underlying cause of the disease.

In addition to mucolytics like dornase alfa, hypertonic saline inhalation has been proposed as a therapy for increasing the hydration of airway surface liquid in cystic fibrosis patients. Pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor,tezacaftor) may be used to treat patients with cystic fibrosis.

The current cystic fibrosis treatment is primarily based on CFTR modulators and supportive therapies such as mucolytics, antibiotics, bronchodilators, and others. TRIKAFTA, SYMDEKO, ORKAMBI, and KALYDECO currently dominate the cystic fibrosis market.

Generally, a normal diet with additional energy and unrestricted fat intake is advised. To compensate for malabsorption and the increased energy demand of chronic inflammation, a high-energy and high-fat diet is recommended, along with supplemental vitamins (especially fat-soluble) and minerals. Sometimes cystic fibrosis causes issues that can only be resolved through surgery or another type of medical procedure.

To know more about cystic fibrosis medications, visit @Cystic Fibrosis Treatment Market

Cystic Fibrosis Pipeline Therapies and Key Companies

Learn more about the FDA-approved drugs for cystic fibrosis treatment @Cystic Fibrosis Drugs

Cystic Fibrosis Market Dynamics

The overall prevalence of cystic fibrosis is expected to rise over the forecast period, creating new opportunities for pharma players in the cystic fibrosis market. Moreover, existing therapies have room for label expansions to improve efficacy, propelling the cystic fibrosis market forward.

Furthermore, there are lucrative opportunities to address unmet therapeutic needs in the cystic fibrosis market regarding tolerability, drug resistance, dosage, and adverse effects. More combinational drugs with higher efficacy are needed.

With advancements in diagnostic tools and palliative care, the median cystic fibrosis life expectancy in the United States has risen from a few months to 46 years. Several cystic fibrosis drugs are currently being used to treat cystic fibrosis, with evidence ranging from randomized, double-blind, placebo-controlled clinical trials to anecdotal case reports. Many more are currently in the works. Pharma companies have been proactive in their research in the cystic fibrosis market, recognizing that the treatment has a long way to go.

However, due to the lack of significant competitors, the current cystic fibrosis market players will likely maintain their competitive positions throughout the study period. Despite improved outcomes, most cystic fibrosis patients die from pulmonary complications, making this one of the most significant underlying challenges in the cystic fibrosis treatment paradigm.

Moreover, the patient's pharmacological treatment history is complicated, with a plethora of drugs resulting in resistance and a constant shift in treatment regimens. Any generic drug entry will impede the cystic fibrosis market for branded drugs. Even Vertex has plans for generic cystic fibrosis medications.

Report Metrics

Details

Study Period

20192032

Coverage

7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Base Year

2021

Market CAGR

9%

Market Size in 2021

USD 7.1 Billion

Key Cystic Fibrosis Companies

Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, Laurent Pharmaceuticals Inc., Krystal Biotech, Translate Bio, Novartis, Algi Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Galapagos NV, PathBio Analytics, AstraZeneca, AxentisPharma AG, and others

Key Cystic Fibrosis Therapies

Ensifentrine, ELX-02, VX-121/TEZ/ VX-561, POL6014 (Lonodelestat), LAU-7b, and others

Scope of the Cystic Fibrosis Market Report

Discover more about drugs for cystic fibrosis in development @Cystic Fibrosis Clinical Trials

Table of Contents

1.

Cystic Fibrosis Market Key Insights

2.

Cystic Fibrosis Market Report Introduction

3.

Cystic Fibrosis Market Overview at a Glance

4.

Cystic Fibrosis Market Executive Summary

5.

Disease Background and Overview

6.

Cystic Fibrosis Treatment and Management

7.

Cystic Fibrosis Epidemiology and Patient Population

8.

Patient Journey

9.

Cystic Fibrosis Marketed Drugs

10.

Cystic Fibrosis Emerging Drugs

11.

Seven Major Cystic Fibrosis Market Analysis

12.

Cystic Fibrosis Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Cystic Fibrosis Market Drivers

16.

Cystic Fibrosis Market Barriers

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Cystic Fibrosis Epidemiology Forecast

Cystic Fibrosis Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the cystic fibrosis epidemiology trends.

Cystic Fibrosis Pipeline

Cystic Fibrosis Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key cystic fibrosis companies, including Verona Pharmaceuticals, Eloxx Pharmaceuticals, Inc., Vertex Pharmaceuticals, Santhera Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Market

Non-Cystic Fibrosis Bronchiectasis Market Insight, Epidemiology, and Market Forecast 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Pipeline

Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2022 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key non-cystic fibrosis bronchiectasis companies, including AstraZeneca, Insmed, Novartis, CSL Behring, Arrowhead Pharmaceuticals, among others.

Non-Cystic Fibrosis Bronchiectasis Epidemiology

Non-Cystic Fibrosis Bronchiectasis Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the non-cystic fibrosis bronchiectasis epidemiology trends.

Read the original:

Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight - PR Newswire

The Columbus Crew is in their final month of matches with only 30 days until MLS Decision Day. The Crews final month begins with a tough matchup against CF Montral. Back on Aug. 3, it was former Black & Gold forward Kei Kamara and Montral coming out of a late storm delay to score two goals in a 2-1 victory at Lower.com Field. Now its time for the away leg of the Eastern Conference showdown and the Massive Report staff members have their ideas on how the night will go for Columbus.

Before those predictions are revealed, heres how the group has done so far in 2022:

Now lets see their Friday night predictions.

The Crew travel to Montreal for a potential preview of the Eastern Conference playoffs. Montreal is one of the better teams in the East and has been very good at home this year.

This match should be an entertaining match similar to the one at Lower.com Field earlier this year. Montral will take the lead in the first half before the Crew battle back and tie the match through Cucho Hernandez in the second half to take a point. Columbus Crew 1 CF Montreal 1

The Crew managed to score only one goal in its two-match home stand against Inter Miami and the Chicago Fire. The offensive woes arent coming at the best time as the push for the playoffs is coming to a head and every point earned is worth its weight in gold.

Luckily for the Black & Gold, Montral has allowed 45 goals this season, 14 more than Columbus. What that means is that the Crew should be able to score a goal Friday night in Quebec.

However, I think it will take at least two goals to get a result in Friday nights match and Im not sure Columbus has that in them. Crew lose in Montreal despite a goal scored by Cucho Hernandez.CF Montreal 2 Columbus Crew 1

Columbus needs to win on Friday, no excuses. With the gap between the Crew and the rest of the Eastern Conference closing, three points will be a minimum when the Black & Gold take on Montreal.

Montreal this season has been electric, sitting in second place in the East. While this game is a must-win, in classic Columbus fashion, the team will tie. Again, a point is better than none, but If the Crew really wants to be serious about getting into the MLS Cup playoffs, the team needs to start picking up wins fast.Columbus Crew 1 CF Montreal 1

The Columbus Crew travels north to take on CF Montreal. While Columbus has had good road form and only has lost once in the last 15 matches, the lone loss comes at the hands of Montreal and it will not be any different in Canada.

Kei Kamara will continue to get revenge on his former team, scoring another goal against the Crew. The Black & Gold will fight back getting one back but ultimately lose. CF Montreal 3 Columbus Crew 1

The Crew has had an impressive run of late when it comes to not losing games, but unfortunately, there havent been many wins in that 15-game stretch. Another tie last week against the Chicago Fire showed that Cucho Hernandez wasnt the cure-all for this offense. This team isnt exactly trending up as the season comes closer to the end and I think this match at CF Montreal will actually be a trend down as the Black & Gold take on a good team on their home field.CF Montreal 2 Columbus Crew 1

CF Montral represents Columbus toughest test for the rest of the season. Fortunately, the Crew hasnt lost twice against the same team in 2022, and I dont think it happens Friday either.

Thats not to say there wont be goals for the home side. Id be a fool to say the Crew has set pieces figured out, based on the seasons tough record on corners. Montrals Kei Kamara will score a headed goal putting the home side up early.

Columbus will battle back, with Cucho Hernndez scoring a goal. I think that the Crew will then shock Montral and Columbus own supporters by pulling out a late match-winning goal from midfielder Lucas Zelarayn.Columbus Crew 2 CF Montreal 1

Make your predictions for tonights match up north. Reply in the comments below or on our Facebook or Twitter pages.

Read this article:

Massive Predictions: Columbus Crew at CF Montral - Massive Report

What happened

Ah, the power of the celebrity shout-out. Special purpose acquisition company (SPAC) CF Acquisition Corporation VI (CFVI -2.36%), which if all goes according to plan will be the vehicle bringing video site Rumble public, can certainly attest to that. CF's shares shot nearly 14% higher on Tuesday, thanks almost exclusively to several mentions on a popular podcast.

On Tuesday's edition of The Joe Rogan Experience, the namesake host positively mentioned Rumble several times in discussions with his guests. Regarding the video site, Rogan said, "They're starting to do some stuff where they are getting bigger and bigger names... and if they do that, and it becomes popular enough, and they can operate the way they are doing now, with no censorship, it's a very interesting alternative."

Rumble has positioned itself as a "free and open" alternative to top video sites -- like Alphabet's YouTube -- which it strongly implies censor views that don't align with their philosophies.

Rogan is hardly a stranger to Rumble. Earlier this year the site offered the highly popular podcaster $100 million to migrate from his show's current home, Spotify, but Rogan turned it down, stating in one of his standup comedy appearances that "Spotify has hung in with me, inexplicably. Let's see what happens."

While it's always nice for investors when a famous person talks up their company, at the end of the day it rarely makes any difference to its operations. I don't think today's gain is indicative of the general sentiment on CF Acquisition, which remains wobbly in light of the struggles of Digital World Acquisition Corp.

Digital World is the SPAC linked to Trump Media and Technology Group, which controls the struggling social media site Truth Social that features content from ex-President Donald Trump.

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet (A shares), Alphabet (C shares), and Spotify Technology. The Motley Fool has a disclosure policy.

Follow this link:

Why CF Acquisition Corp. VI Blasted 14% Higher Today - The Motley Fool

The upcoming game between Real Betis and Villarreal CF is on September 11, starting at 3:00 PM ET.

Villarreal took on Elche CF at home in its last match and prevailed by a final score of 4-0. It took 15 shots, outshooting Elche CF by 11. Villarreal was led by four different goal-scorers, including Gerard Moreno, who each had one of their sides goals against Elche CF.

In its most recent outing on September 3, Real Betis suffered a 2-1 road loss by Real Madrid, and recorded 13 fewer shots than Real Madrid. Sergio Canales recorded his teams only goal in the match.

Ahead of watching this matchup, here is everything you need to know about Sundays soccer action.

For more soccer coverage, check out our new website Pro Soccer Wire.

Soccer odds courtesy of Tipico Sportsbook. Odds updated Tuesday at 6:31 PM ET.

Want to get in on the soccer action? Place your legal sports bets on this game or others in CO, NJ at Tipico Sportsbook. New customer offer: Deposit $10, GET $200 in betting credits immediately. 21+, Terms and Conditions apply. Bet now!For more soccer coverage, check out our new website Pro Soccer Wire.

Gannett may earn revenue from Tipico for audience referrals to betting services. Tipico has no influence over nor are any such revenues in any way dependent on or linked to the newsrooms or news coverage. See Tipico.com for Terms and Conditions. 21+ only. Gambling problem? Call 1-800-GAMBLER (NJ), 1-800-522-4700 (CO), 1-800-BETS-OFF (IA).

See more here:

Watch Real Betis vs. Villarreal CF Online: Live Stream, Start Time - For The Win

The upcoming match between Real Sociedad and Getafe CF will happen at Coliseum Alfonso Prez in Getafe, Spain on Sunday, September 11, starting at 12:30 PM ET.

Real Sociedad drew its last game, 1-1, against Atletico Madrid at home on September 3. Atletico Madrid outshot Real Sociedad by a margin of 13 to seven. Umar Sadiq picked up his clubs only goal to lead the team offensively against Atletico Madrid.

In its last match on September 4, Getafe fell to Valencia CF 5-1 on the road. Valencia CF outshot Getafe 17 to seven. Gaston Alvarez scored Getafes only goal on one shot.

Get ready for this matchup with everything you need to know before Sundays soccer action.

For more soccer coverage, check out our new website Pro Soccer Wire.

Soccer odds courtesy of Tipico Sportsbook. Odds updated Tuesday at 1:31 PM ET.

Want to get in on the soccer action? Place your legal sports bets on this game or others in CO, NJ at Tipico Sportsbook. New customer offer: Deposit $10, GET $200 in betting credits immediately. 21+, Terms and Conditions apply. Bet now!For more soccer coverage, check out our new website Pro Soccer Wire.

Gannett may earn revenue from Tipico for audience referrals to betting services. Tipico has no influence over nor are any such revenues in any way dependent on or linked to the newsrooms or news coverage. See Tipico.com for Terms and Conditions. 21+ only. Gambling problem? Call 1-800-GAMBLER (NJ), 1-800-522-4700 (CO), 1-800-BETS-OFF (IA).

See the rest here:

Watch Getafe CF vs. Real Sociedad Online: Live Stream, Start Time - For The Win

Mauro Icardi is under contract with Paris Saint-Germain until June 2024, but has been told to look elsewhere for minutes this campaign. The 29-year-old has not played a game with the Ligue 1 side so far this season and was even left out of the UEFA Champions League roster.

The Argentina international has been linked with a move to Galatasaray because the transfer window closes on 8 September in the Turkish league. Icardi is also rumored to be considering an offer from Major League Soccer side Inter Miami, but he will not be able to join as a designated player as the three slots are occupied.

Icardi doesnt have too many offers on the table and needs to make a decision soon. Last season the 29-year-old made 30 appearances across all competitions with PSG, scoring five goals in a total of 1,207 minutes.

In order for the deal to come through with Inter Miami, Icardi will have to end his contract with the Ligue 1 side and become a free agent. The David Beckham-owned team has six games left in the regular season and are trying to secure a spot in the 2022 MLS Cup playoffs.

See the original post here:

Mauro Icardi linked with move to Inter Miami CF - AS USA

'Rumble Exclusives' will challenge the status quo by delivering independent content premised on creative independence while empowering audiences to have a two-way dialogue with creators

TORONTO, Sept. 8, 2022 /PRNewswire/ -- Rumble, the video sharing platform, announced plans to launch 'Rumble Exclusives,' an innovative livestreaming lineup featuring independent creators and a two-way dialogue with their audiences.

In the coming months, the company plans to sign top-tier creative talent to fill a daily lineup of livestreams leveraging the Rumble platform and Rumble's community-based subscription platform, Locals. The first daily livestream, hosted by Pulitzer Prize-winning journalist Glenn Greenwald, will start later this month. The programs will consist of a livestreamed show on Rumble.com followed by a live two-way dialogue on Locals, between the creator and their subscribing audience on Locals.com. The two-way dialogue represents a major step forward for how media is consumed by empowering audiences to ask questions and for creators to defend their views, as opposed to the traditional one-way media approach.

"The writing is on the wall for the credibility of corporate media," said CEO Chris Pavlovski. "Everyone in the world should have access to unfiltered content, raw opinion, and more importantly, should be able to engage in a two-way dialogue with truly independent creators," he continued. "For too long, we have been at the mercy of corporate narratives. At Rumble and Locals, we firmly believe that independent creators will unshackle audiences from these narratives and allow everyone to reach their own unbiased and educated conclusions."

Rumble is a high-growth neutral video platform that is creating the rails and independent infrastructure designed to be immune to cancel culture. Rumble's mission is to restore the Internet to its roots by making it free and open once again. In December 2021, the company announced the execution of a definitive business combination agreement with CF Acquisition Corp. VI CFVI. See the announcement here: https://corp.rumble.com

SOURCE Rumble and CFVI

Read this article:

CF Acquisition (NASDAQ:CFVI) Rumble Takes On Traditional Media Outlets With New 'Rumble Exclusives' Liv - Benzinga

Austin Slater couldn't track down Trayce Thompson's fly ball Thursday night.

The Giants were only charged with two errors in their rollicking loss to the Dodgers on Thursday night, but it was two defensive miscues where their gloves didn't even touch the ball that arguably cost them the game.

The most poorly timed came with two outs in the bottom of the eighth and the Giants clinging to a 6-5 lead. Austin Slater, who had entered the game to pinch hit for Mike Yastrzemski, is usually the least of the Giants' defensive problems. Unfortunately for him, he ran into the wall on a deep fly ball, losing his glove over the wall and givingTrayce Thompson (Klay's younger brother) an easy triple. The inning stayed alive long enough for Mookie Betts to hit what ended up being the game-winning three-run homer.

Luis Gonzalez's third-inning adventure was slightly more forgivable, but still cost the Giants two runs. With two outs, Justin Turner lofted an easy fly ball to deep right ... and Gonzalez lost it in the lights, doubling the lead to 4-0.

It was a familiar scene for the Giants, who sit a game outside of the second wild card spot. Team president Farhan Zaidi admitted to the San Francisco Chronicle on Tuesday that defense was the main reason they weren't in playoff position. (SFGATE and the San Francisco Chronicle are both owned by Hearst but operate independently of one another.)

Earlier this month, longtime Giants writer Grant Brisbee called the team "a bunch of clankmitts" and said it "might be the worst defensive team I remember watching." (He also pointed out that by at least one metric, these Giants are among the worst defensive teamsever.) Retooling a struggling defense on the fly is not easy, but it might be Zaidi's only hope at coming anywhere close to recapturing last year's magic.

Dennis Young is the SFGATE sports editor. He can be reached at dennis.young@sfgate.com

Read the original post:

SF Giants CF struggles on triple by Klay's brother - SFGATE

DEERFIELD, Ill.--(BUSINESS WIRE)--Today, the U.S. International Trade Commission (ITC) made a negative final injury determination concerning its investigation of imports of urea ammonium nitrate solutions (UAN) from Russia and Trinidad and Tobago (Trinidad).

We are disappointed that the International Trade Commission has determined the U.S. UAN industry has not been harmed by the unfair trade practices from state-subsidized entities underpinning UAN imports from Russia and Trinidad that were clearly established through thorough and impartial investigations by the U.S. government, said Tony Will, president and chief executive officer, CF Industries Holdings, Inc. Unfortunately, this outcome will perpetuate an unlevel playing field for a domestic industry that has invested billions of dollars in the U.S. to ensure American farmers have a reliable source of UAN fertilizer.

Todays ITCs decision follows the U.S. Department of Commerces (Commerce) final affirmative AD/CVD determinations in June 2022. Commerce found that imports from Russia are dumped (i.e., sold at less than fair value) at rates ranging from 8.16% to 122.93%, and unfairly subsidized at rates ranging from 6.27% to 9.66%. In addition, Commerce found that imports from Trinidad are dumped at a rate of 111.71% and unfairly subsidized at a rate of 1.83%.

Commerce and the ITC initiated their investigations in July 2021 in response to petitions filed by CF Industries through certain of its production facilities.

About CF Industries Holdings, Inc.

At CF Industries, our mission is to provide clean energy to feed and fuel the world sustainably. With our employees focused on safe and reliable operations, environmental stewardship, and disciplined capital and corporate management, we are on a path to decarbonize our ammonia production network the worlds largest to enable green and blue hydrogen and nitrogen products for energy, fertilizer, emissions abatement and other industrial activities. Our nine manufacturing complexes in the United States, Canada, and the United Kingdom, an unparalleled storage, transportation and distribution network in North America, and logistics capabilities enabling a global reach underpin our strategy to leverage our unique capabilities to accelerate the worlds transition to clean energy. CF Industries routinely posts investor announcements and additional information on the Companys website at http://www.cfindustries.com and encourages those interested in the Company to check there frequently.

Go here to see the original:

CF Industries Holdings, Inc. Statement Regarding ITC Injury Determination Concerning Imports of UAN from Russia and Trinidad and Tobago - Business...